[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 1987

PUVA, Etretinate, and PUVA-Etretinate Therapy for Pustulosis PalmoplantarisA Placebo-Controlled Comparative Trial

Author Affiliations

From the Department of Dermatology, University of Göteborg (Sweden).

Arch Dermatol. 1987;123(7):885-889. doi:10.1001/archderm.1987.01660310053013

• Thirty patients with severe pustulosis palmoplantaris completed a placebo-controlled comparative trial. Patients were randomly allocated to placebo or etretinate therapy; after two weeks, psoralen plus long-wave ultraviolet light (PUVA) treatment was instituted on one hand or foot, while the other hand or foot served as an untreated control. Fourteen of 18 hands or feet cleared with the combined treatment, compared with three of 18 with etretinate treatment and three of 12 with PUVA treatment. Follow-up showed a high relapse rate. Treatment of severe pustulosis palmoplantaris must be individualized to minimize short- and long-term side effects.

(Arch Dermatol 1987;123:885-889)